ofa tirzepatide Bests Semaglutide for Real-World Weight Loss FDA says years-long tirzepatide shortage

Description

Case Numbers Skyrocketing: From just 58 lawsuits in March 2024 to over 10,000 cases by mid-2025

Starting with the lowest recommended dose, eating smaller meals, staying hydrated, prioritizing protein, and following your prescribed dose-escalation schedule can help improve comfort during the adjustment period

Supplements That Increase GLP-1 While diet and lifestyle remain the foundation, certain nutrients are being studied as supplements that increase GLP-1

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial Summary: SURPASS-4 was a Phase 3, open-label, randomized trial comparing tirzepatide (5 mg, 10 mg, or 15 mg once weekly) with insulin glargine once daily in patients with type 2 diabetes and increased cardiovascular risk whose glucose levels were inadequately controlled